Progyny

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm’s network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Progyny reports record growth in 2022, eyes sustained success

Progyny's exceptional performance in 2022, driven by record revenue growth and client additions, positions the company for continued success in 2023.
The company's strengths in provider network retention, strong gross margins, and strategic investments highlight its competitive advantage and growth potential.
Challenges such as tightening growth rates and margin sustainability require proactive strategies, while opportunities in market positioning and growth avenues offer promising prospects.
With a strong pipeline, focus on enhancing services, and commitment to growth, Progyny is poised to capitalize on market demand and drive further success.

Progyny reports record Q1 growth, raises 2023 guidance amid strong demand

Progyny's Q1 2023 performance reflects robust growth, operational efficiency, and a strategic focus on expanding market reach and service offerings. Despite potential challenges, the company remains optimistic about future prospects, raising guidance for 2023 and highlighting strong demand for fertility benefits.

Progyny reports record revenue and strong growth outlook for 2023

Progyny's Q2 2023 earnings call highlighted exceptional financial performance, strong operational metrics, and a positive outlook for future growth. The company's focus on quality care, cost containment, and market trends positions it well for continued success in the reproductive health industry.
With a robust PBM model, unique contracting approach, and commitment to data-driven outcomes, Progyny stands out as a leader in the sector. The expansion into menopause services and partnerships further strengthens its competitive edge and diversifies its service offerings.
While Progyny faces challenges in market penetration and operational scalability, the company's strategic strengths and growth opportunities present a promising outlook. By navigating industry challenges and leveraging emerging trends, Progyny is poised for sustained growth and innovation.

Progyny reports record Q3 earnings, eyes growth through diversification

Progyny's Q3 performance reflects robust growth, strong client relationships, and strategic expansion initiatives.
Despite challenges in Q4 and Progyny Rx contribution decline, the company is well-positioned for sustained growth.
Opportunities lie in diversifying services, addressing economic concerns, and leveraging partnerships for future expansion.
Overall, Progyny's proactive strategies and solid financial performance signal a promising outlook for continued success.

Progyny excels in 2023, eyes diversified growth in 2024

Progyny's exceptional 2023 performance and client-focused approach position it as a leader in fertility care.
While facing revenue challenges in Q1, Progyny's strategic initiatives and market opportunities offer avenues for growth.
The company's resilience in member activity and diversified revenue streams bode well for sustained success.
Progyny's expansion plans and competitive wins underscore its strong market position and growth potential.

Progyny reports strong Q1 performance, eyes growth opportunities ahead

Progyny's Q1 showed strength but faced challenges in utilization and revenue.
The company's business model demonstrated leverage and solid financial performance.
Opportunities lie in market trends, expanding services, and employer conversations.
Guidance for Q2 and full-year adjusted EBITDA indicates growth trajectory.
Progyny's focus on women's health and family building positions it for future success.

Progyny reports 9% revenue growth in Q2 2024 earnings call

Progyny delivered solid financial performance in Q2 2024, with revenue and gross profit showing healthy growth rates.
Despite challenges in forecasting and membership growth, the company's operational strengths and cash flow generation are notable.
Adjustments to revenue guidance reflect proactive management in response to market dynamics, while opportunities for growth and efficiency improvements are evident.
Overall, Progyny's Q2 performance highlights resilience and strategic focus amidst evolving market conditions.

Progyny reports mixed Q3 performance, focuses on client growth

Progyny faced challenges in member activity and gross margin in Q3 2024.
Despite this, positive selling season results and strong client commitments were noted.
Renewals and upsell activities remained robust, supporting revenue guidance.
The company's focus on care management services and cash flow stability is evident.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 3:50 P.M. Eastern Time.

Progyny, Inc. to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Progyny (PGNY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Here's What Could Help Progyny (PGNY) Maintain Its Recent Price Strength

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, along with RMA of Connecticut, RMA of New York, and Stanford University partnered on the largest research study on decision making by single or coupled intended fathers in their family building using assisted reproductive technology (ART) treatment to become parents.

Largest Research Study on Decision Making of Single or Coupled Intended Fathers Selected for Presentation at 2021 ACOG Annual Clinical and Scientific Meeting and 69th Annual Pacific Coast Reproductive Society Meeting

DENVER, May 19, 2021 /PRNewswire/ -- Family planning and fertility benefits are becoming more mainstream with employers seeking to demonstrate inclusivity and attract or retain talent. As women become mothers later in their career and same-sex couples or single people seek to have children, there has been greater interest and expectations for these benefits.

Welltok Welcomes Maven and Progyny to its Connect Ecosystem Family

Progyny, Inc. (PGNY) CEO David Schlanger on Q1 2021 Results - Earnings Call Transcript

NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the BofA Securities 2021 Health Care Conference on Wednesday, May 12, 2021 at 10:15 A.M. Eastern Time.

Progyny, Inc. to Present at the BofA Securities 2021 Health Care Conference

Reports Record First Quarter Revenue of $122.1 Million, Reflecting 51% GrowthIssues Revenue Guidance of $126.0 to $131.0 Million for the Second Quarter of 2021, Reflecting Growth of 95% to 103%Continues to Demonstrate Leverage in Operating Model Through Increased Profitability

Progyny, Inc. Announces First Quarter 2021 Results

NEW YORK, April 22, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, will report its financial results for the quarterly period ended March 31, 2021 after the close of the market on Thursday, May 6, 2021.

Progyny, Inc. Announces Details for Its First Quarter 2021 Results Report

Lattice Semiconductor

S&P Global

Tyler Technologies

Domtar

Varian Medical Systems

NEW YORK, April 15, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 effective prior to the open of trading on Tuesday, April 20: S&P MidCap 400 constituent PTC Inc. (NASD:PTC) will replace Varian Medical Systems Inc. (NYSE:VAR) in the S&P 500, and Lattice Semiconductor Co. (NASD:LSCC) will replace PTC in the S&P MidCap 400. Siemens Healthineers AG (XETR: SHL) acquired Varian Medical Systems Inc. in a deal that closed today, April 15.

PTC Set to Join S&P 500; Lattice Semiconductor & Progyny to Join S&P MidCap 400; Domtar to Join S&P SmallCap 600

AstraZeneca

Cannae Hlds

When a company's return on equity ratio tops most of its competitors, it indicates the company has been very efficient in generating earnings.

3 Stock Picks With High Returns on Equity

AbbVie

Adobe

General Motors

KLA-Tencor

Netflix

NIKE

Omnicom Group

Penumbra

Constellation Brands

Tesla

Netflix and Facebook are among the top stocks for April. Q.ai's Artificial Intelligence has also dug up top tech stocks, top consumer stocks, top quality value stocks, and top growth stocks.

Top Stocks To Buy This Month Amid Optimistic Markets

Laureate Education

Pinterest

Redfin

Zovio

As the major indices drop with fears of rising bond yields, Q.ai's Artificial Intelligence has assessed each firm to bring you today's best short plays.

Top Stocks To Short Today Amid Bond Headwinds

FTAI Aviation Ltd

Liberty Media Corp-Liberty Formula One

Amid real potential for another sell-off, the deep learning algorithms at Q.ai have crunched the data to give you top shorts for today.

Top Stocks To Short Today As Major Indices Trade In The Red

Livent Corp

RBC Bearings

All major indices are projected to end the week with losses, as the Dow Jones fell 70 points, the S&P 500 traded flat, and the Nasdaq ﻿mildly gained 0.2%. But Q.ai's ﻿deep learning algorithms can help you beat the market with today's best short plays.

Top Stocks To Short Today After Fed's Major Bank Decision

Progyny, a company that handles fertility benefits for other companies, managed to close out 2020 with more customers. Meanwhile, Progyny stock scored a respectable gain during the year.

Progyny Stock: Benefits Manager Grows Even As Covid Upends Fertility Treatments

Cal-Maine Foods

Carvana

TripAdvisor

Growth stocks opened the day with significant losses as the 10-year yield climbed to its highest level since last January. But Q.ai's deep learning algorithms have assessed the data to bring you today's best short plays.

Top Stocks To Short Today As Investors Buckle Up For Bond Yields

Although the Dow Jones gained 40 points, the S&P 500 fell 0.4%, and the Nasdaq dropped 1.1%. Q.ai's deep learning algorithms are here to help you make the most of this market with today's best short plays.

Top Stocks To Short Today As The Fed Keeps Investors On Their Toes

Stocks have dropped again due to bond yields. In the meantime, Q.ai's Artificial Intelligence has assessed the data to bring you today's best short plays.

Top Stocks To Short Today As Market Struggles To Reverse Losing Streak

Progyny, Inc. (PGNY) CEO David Schlanger on Q4 2020 Results - Earnings Call Transcript

Fertility-benefits manager Progyny topped fourth-quarter estimates but gave cautious guidance late Wednesday. The post Progyny Beats As Fertility Clients Jump Amid Pandemic But Outlook Weak appeared first on Investor's Business Daily.

Progyny Beats As Fertility Clients Jump Amid Pandemic But Outlook Weak

Reports Record Fourth Quarter Revenue of $100.3 MillionIssues Revenue Guidance of $520.0 to $540.0 Million for 2021, Reflecting Growth of 51% to 57%

Progyny, Inc. Announces Fourth Quarter and Full Year 2020 Results

CuriosityStream

2 High-Growth Stocks in the Market Today

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny's Chief Executive Officer, and Mark Livingston, Progyny's Chief Financial Officer, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:40 A.M. Eastern Time.

Progyny, Inc. to Participate at the 10th Annual SVB Leerink Global Healthcare Conference

Invitae

Vertex Pharmaceuticals

Two innovative small companies with scorching growth and one bargain biotech.

3 Healthcare Stocks I'd Buy Right Now

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, will report its financial results for the quarterly period and full year ended December 31, 2020 after the close of the market on Wednesday, February 24, 2021.

News for Progyny Stock (PGNY)